Lexeo Therapeutics, Inc.
Income Statement
| Line Item | FY2022 |
|---|---|
| Revenue | $654.0K |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $49.2M |
| SG&A Expense | $12.0M |
| Operating Income | $-60.5M |
| Operating Margin | -9,252.1% |
| Interest Expense | $91.0K |
| Pretax Income | $-59.3M |
| Income Tax Expense | — |
| Net Income | $-59.3M |
| Net Margin | -9,063.8% |
| EPS (Basic) | $-2.02 |
| EPS (Diluted) | $-2.02 |
| Shares Outstanding (Basic) | 29.3M |
| Shares Outstanding (Diluted) | 29.3M |
| Dividends Per Share | — |